"Non squamous non small cell lung cancer" trang 1 - tải miễn phí từ tailieunhanh
Increased IR-A/IR-B ratio in non-small cell lung cancers associates with lower epithelialmesenchymal transition signature and longer survival in squamous cell lung carcinoma

Increased IR-A/IR-B ratio in non-small cell lung cancers associates with lower epithelialmesenchymal transition signature and longer survival in squamous cell lung carcinoma
10    51    1
The clinical significance of Psoriasin for non-small cell lung cancer patients and its biological impact on lung cancer cell functions

The clinical significance of Psoriasin for non-small cell lung cancer patients and its biological impact on lung cancer cell functions
10    83    1
Differential efficacy of cisplatin plus pemetrexed between L858R and Del-19 in advanced EGFR-mutant non-squamous non-small cell lung cancer

Differential efficacy of cisplatin plus pemetrexed between L858R and Del-19 in advanced EGFR-mutant non-squamous non-small cell lung cancer
8    69    1
Randomized phase II study of pemetrexed/cisplatin with or without axitinib for non-squamous non-small-cell lung cancer

Randomized phase II study of pemetrexed/cisplatin with or without axitinib for non-squamous non-small-cell lung cancer
10    39    1
Efficacy and safety of maintenance immune checkpoint inhibitors with or without pemetrexed in advanced non-squamous non-small cell lung cancer: A retrospective study

Efficacy and safety of maintenance immune checkpoint inhibitors with or without pemetrexed in advanced non-squamous non-small cell lung cancer: A retrospective study
9    29    1
Phase II study of axitinib with doublet chemotherapy in patients with advanced squamous non–small-cell lung cancer

Phase II study of axitinib with doublet chemotherapy in patients with advanced squamous non–small-cell lung cancer
10    38    1
Randomized, open-label phase II study of brigatinib and carboplatin plus pemetrexed and brigatinib alone for chemotherapy-naive patients with ALK-rearranged non-squamous non-small cell lung cancer: Treatment rationale and protocol design of the B-DASH study (WJOG 14720 L)

Randomized, open-label phase II study of brigatinib and carboplatin plus pemetrexed and brigatinib alone for chemotherapy-naive patients with ALK-rearranged non-squamous non-small cell lung cancer: Treatment rationale and protocol design of the B-DASH study (WJOG 14720 L)
6    1    1
Phase II study of bevacizumab, cisplatin, and docetaxel plus maintenance bevacizumab as first-line treatment for patients with advanced non-squamous non-small-cell lung cancer combined with exploratory analysis of circulating endothelial cells: Thoracic Oncology Research Group (TORG)1016

Phase II study of bevacizumab, cisplatin, and docetaxel plus maintenance bevacizumab as first-line treatment for patients with advanced non-squamous non-small-cell lung cancer combined with exploratory analysis of circulating endothelial cells: Thoracic Oncology Research Group (TORG)1016
8    56    1
Network meta-analysis of first-line immune checkpoint inhibitor therapy in advanced non-squamous non-small cell lung cancer patients with PD-L1 expression≥50%

Network meta-analysis of first-line immune checkpoint inhibitor therapy in advanced non-squamous non-small cell lung cancer patients with PD-L1 expression≥50%
12    1    1
Protective effect of bevacizumab on chemotherapy-related acute exacerbation of interstitial lung disease in patients with advanced non-squamous non-small cell lung cancer

Protective effect of bevacizumab on chemotherapy-related acute exacerbation of interstitial lung disease in patients with advanced non-squamous non-small cell lung cancer
10    37    1
Prediction of pathologic stage in non-small cell lung cancer using machine learning algorithm based on CT image feature analysis

Prediction of pathologic stage in non-small cell lung cancer using machine learning algorithm based on CT image feature analysis
12    60    0
The MYCN-HMGA2-CDKN2A pathway in non-small cell lung carcinoma - differences in histological subtypes

The MYCN-HMGA2-CDKN2A pathway in non-small cell lung carcinoma - differences in histological subtypes
12    46    1
Fostering efficacy of anti-PD-1-treatment: Nivolumab plus radiotherapy in advanced non-small cell lung cancer - study protocol of the FORCE trial

Fostering efficacy of anti-PD-1-treatment: Nivolumab plus radiotherapy in advanced non-small cell lung cancer - study protocol of the FORCE trial
11    81    0
Consolidation chemotherapy may improve survival for patients with locally advanced non-small-cell lung cancer receiving concurrent chemoradiotherapy - retrospective analysis of 203 cases

Consolidation chemotherapy may improve survival for patients with locally advanced non-small-cell lung cancer receiving concurrent chemoradiotherapy - retrospective analysis of 203 cases
9    43    2
Correlation between loss of Smad4 and clinical parameters of non-small cell lung cancer: An observational cohort study

Correlation between loss of Smad4 and clinical parameters of non-small cell lung cancer: An observational cohort study
14    39    1
Extraordinary response to crizotinib in a woman with squamous cell lung cancer after two courses of failed chemotherapy

Extraordinary response to crizotinib in a woman with squamous cell lung cancer after two courses of failed chemotherapy
4    44    5
Signaling protein signature predicts clinical outcome of non-small-cell lung cancer

Signaling protein signature predicts clinical outcome of non-small-cell lung cancer
12    52    1
A randomized phase II clinical trial of nab-paclitaxel and carboplatin compared with gemcitabine and carboplatin as first-line therapy in locally advanced or metastatic squamous cell carcinoma of lung

A randomized phase II clinical trial of nab-paclitaxel and carboplatin compared with gemcitabine and carboplatin as first-line therapy in locally advanced or metastatic squamous cell carcinoma of lung
4    50    1
Modulation of chemoimmunotherapy efficacy in non-small cell lung cancer by sex and histology: A real-world, patient-level analysis

Modulation of chemoimmunotherapy efficacy in non-small cell lung cancer by sex and histology: A real-world, patient-level analysis
8    42    3
NQO1 protein expression predicts poor prognosis of non-small cell lung cancers

NQO1 protein expression predicts poor prognosis of non-small cell lung cancers
9    43    1